InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET
Vancouver, British Columbia--(Newsfile Corp. - January 18, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, will be participating in the Water Tower Research Fireside Chat Series on January 25, 2024, at 1:00 pm ET. This event is open access for all investors. Topics will include: An overview of InMed's pharmaceutical pipeline in Alzheimer's and...
2024-01-18 4:41 PM EST
InMed Pharmaceuticals Provides Business Update and Milestones for 2024
Vancouver, British Columbia--(Newsfile Corp. - January 16, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today outlines key accomplishments from 2023 and provides key strategic priorities for 2024. Eric A. Adams, InMed President and CEO, com
2024-01-16 8:00 AM EST
InMed Announces Results of 2023 Annual General Meeting
Vancouver, British Columbia--(Newsfile Corp. - December 19, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today confirmed that, at its annual general meeting of shareholders held on December 19, 2023 (the "Meeting"), all of the matters put forward before shareholders for consideration and approval as set out in InMed's notice of meeting and...
2023-12-19 6:03 PM EST
InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration
Vancouver, British Columbia--(Newsfile Corp. - November 29, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announces the launch of INM-089, a cannabinol ("CBN") analog, to investigate its effects in the treatment of Age-related Macular Degeneration ("AMD"). INM-089 is the company's second ocular pharmaceutical program....
2023-11-29 8:00 AM EST
InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - November 14, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today reports financial results for the first quarter of the fiscal year 2024 which ended September 30, 2023. The Company's full financial statements and related MD&A for the first quarter ended September 30, 2023, are...
2023-11-14 8:04 AM EST
InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023
Vancouver, British Columbia--(Newsfile Corp. - November 2, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced that an abstract describing the Phase 2 clinical study of investigational drug INM-755 cannabinol ("CBN") cream for the treatment of symptoms in patients with epidermolysis bullosa ("EB"), a rare genetic skin...
2023-11-02 8:00 AM EDT
InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules
Vancouver, British Columbia--(Newsfile Corp. - October 26, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced that it has closed its previously announced offering for the issuance and sale of 3,012,049 pre-funded warrants and preferred investment options to purchase up to an aggregate of 3,012,049 common shares, at a...
2023-10-26 7:15 PM EDT
InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules
Vancouver, British Columbia--(Newsfile Corp. - October 24, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced that it has entered into definitive agreements for the issuance and sale of 3,012,049 of its common shares (or pre-funded warrants in lieu thereof) and preferred investment options to purchase up to an...
2023-10-24 4:38 PM EDT
InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies
Vancouver, British Columbia--(Newsfile Corp. - October 24, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced it has selected a lead Alz
2023-10-24 7:30 AM EDT
InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - September 29, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs,
2023-09-29 1:21 PM EDT
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
Vancouver, British Columbia--(Newsfile Corp. - September 22, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced the Company received written notice from the listing qualifications department staff of The Nasdaq Capital Market ("Nasdaq") dated September 19, 2023, notifying that the closing bid price of the Company's...
2023-09-22 6:15 PM EDT
InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference
Vancouver, British Columbia--(Newsfile Corp. - September 7, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing, and commercialization of rare cannabinoids and cannabinoid analogs, today announce that the company will be participating in the H.C. Wainwright Global Investment Conference, which takes place September 11-13, 2023, in New York City. The on-demand presentation by InMed's Chief Executive...
2023-09-07 8:30 AM EDT
InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ET
Vancouver, British Columbia--(Newsfile Corp. - July 21, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announce Jerry Griffin, VP of Sales and Marketing for InMed's subsidiary BayMedica LLC ("BayMedica"), a leading supplier of bioidentical rare cannabinoids to the Health and Wellness ("H&W") market, will be participating in...
2023-07-21 7:30 AM EDT
InMed Provides Update on BayMedica Rare Cannabinoid Business
Vancouver, British Columbia--(Newsfile Corp. - July 20, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today provided a commercial and manufacturing update on its subsidiary BayMedica LLC ("BayMedica"), a leading supplier of bioidentical
2023-07-20 7:30 AM EDT
InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa
An exploratory clinical evaluation of the Phase 2 clinical trial data showed a positive indication of enhanced anti-itch activity for INM-755 cannabinol ("CBN") cream versus the control cream alone. The results for non-wound itch were not statistically significant in favor of INM-755 CBN cream due, in part, to the clinically important anti-itch effect of the underlying control cream. INM-755 CBN cream demonstrated a favorable safety and tolerability profile. InMed will pursue strategic...
2023-06-22 7:30 AM EDT
InMed's Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting
Vancouver, British Columbia--(Newsfile Corp. - June 1, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced that results from a neurodegenerative disease study was presented in a scientific poster at the Canadian Neuroscience Meeting in Montreal from May 28-31, 2023. The InMed sponsored research, entitled "Cannabinoids...
2023-06-01 7:30 AM EDT
InMed to Participate in Upcoming Virtual Investor Events
Vancouver, British Columbia--(Newsfile Corp. - May 24, 2023) - InMed Pharmaceuticals Inc. (NASQDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announce that the Company's executive team will be participating in the upcoming virtual investor events: Tribe Public Webinar Date: May 31, 2023 Time: 12:00 PM ET Registration:...
2023-05-24 6:51 PM EDT
InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ET
Vancouver, British Columbia--(Newsfile Corp. - May 18, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announce Eric A. Adams, CEO of InMed, will be participating in the Water Tower Research Fireside Chat Series on May 23, 2023, at 1:00 pm ET. This event is open access for all investors to participate. Topics will include:...
2023-05-18 5:00 PM EDT
InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - May 15, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced financial results for the third quarter of the fiscal year 2023 ("FY 3Q23") which ended March 31, 2023. The Company’s full financial statements and relat
2023-05-15 12:33 PM EDT
InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa
Vancouver, British Columbia--(Newsfile Corp. - March 28, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announced it has concluded enrollment of its Phase 2 clinical trial using investigational drug INM-755 cannabinol ("CBN") cream for the treatment of patients with epidermolysis bullosa ("EB"), a rare genetic skin disease. The Phase 2 study,...
2023-03-28 7:30 AM EDT